Janssen gets diabetes CRL

Share this article:

The FDA issued a Complete Response Letter to Janssen, telling the drugmaker it needs more data about the experimental canagliflozin-metformin treatment for diabetes. The Johnson & Johnson subsidiary said in a statement that the FDA wants data indicating that canagliflozin—known by the brand Invokana, approved earlier this year—is as effective in the combined form as it is when used as a standalone treatment.

PMLive notes that the CRL is not much of a setback for Janssen, because doctors can prescribe the two drugs separately if they want to use them in tandem. The site also notes that the combination is not a unique one—Bristol-Myers Squibb and AstraZeneca are already marketing a dapagliflozin-metformin mix abroad under the brand Xigduo.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.